Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y₁₂ signaling pathway.

ABSTRACT: Ticagrelor is the first reversibly binding oral P2Y₁₂ receptor antagonist to inhibit platelet activation and has been approved by the Food and Drug Administration for the treatment of coronary artery disease. At present, the other pharmacological functions of ticagrelor remain poorly understood. The NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome plays a critical role in the innate immune system, but its excessive activation also contributes to the pathogenesis of complex diseases. In this study, we systematically examined the effects of ticagrelor on the NLRP3 inflammasome and found that ticagrelor inhibits NLRP3 inflammasome activation in macrophages independent of its classic inhibitory effect on the P2Y₁₂ signaling pathway. Further mechanist

SUBMITTER: Huang B 

PROVIDER: S-EPMC8093290 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature